Harvard Medical School - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
87
About the Report
About the Report
Summary
Harvard Medical School (HMS), a subsidiary of Harvard University is a medical institute that offers education, research and clinical care services. The institute offers various degree programs such as bachelor's program, master's program, PhD program, and continuing education. It offers programs in the areas of medical education, health sciences and technology, and medicine. HMS also conducts basic and clinical research studies. The institute offers healthcare services in the fields of anaesthesia, otology and laryngology, pathology, dermatology, pediatrics, emergency medicine, physical medicine and rehabilitation, among others. It operates through medical centers, hospital, and research institutes in Massachusetts. HMS is headquartered in Boston, Massachusetts, the US.
Harvard Medical School-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Harvard Medical School, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Harvard Medical School, Medical Devices Deals, 2012 to YTD 2018 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Harvard Medical School, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Kiromic Enters into Agreement with Harvard Medical School 13
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 14
Imcare Biotech Enters into Partnership with Harvard Medical School 15
Astellas Pharma Enters into Research Agreement with Harvard Medical School 16
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 17
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
Licensing Agreements 20
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Mesoblast Enters into Licensing Agreement with Harvard Medical School 21
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 22
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 23
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School-Key Competitors 27
Harvard Medical School-Key Employees 28
Harvard Medical School-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 29
Recent Developments 30
Government and Public Interest 30
Aug 28, 2018: Ending 40-year quest, scientists reveal 'hearing' protein 30
Aug 16, 2018: NUS and Harvard scientists develop novel drug that could potentially treat liver cancer more effectively 32
Aug 15, 2018: New genome analysis scores risk of serious common diseases 34
Aug 09, 2018: Recording every cell's history in real-time with evolving genetic barcodes 35
Aug 06, 2018: A targeted approach to treating glioma 37
Jun 14, 2018: Milstein Medical Asian American Partnership Foundation Announces 2018 Fellowship and Project Awards 38
May 16, 2018: Bay Area Lyme Foundation's LymeAid 2018 Raises USD 1.1 Million for Lyme Disease Research 41
May 14, 2018: Spatial organization of cells in the inner ear enables the sense and sensitivity of hearing 42
May 10, 2018: USD 5 million supports innovative breast cancer trial 44
Feb 15, 2018: Baylor team shortlisted for Cancer Research UK grants 45
Jan 04, 2018: Researchers create novel compound targeting melanoma cells 46
Dec 11, 2017: USC, Harvard-affiliated hospitals & Mayo Clinic team up to streamline Alzheimer's research 47
Nov 30, 2017: Invasive cells in head and neck tumors predict cancer spread 49
Nov 29, 2017: Researchers Develop New Technique to Model Transplantation of the Human Liver 51
Nov 28, 2017: RSNA Release: Fat Distribution in Women and Men Provides Clues to Heart Attack Risk 52
Oct 31, 2017: From Bench to Bedside: USD 4 Million Gift Supports Translational Medicine 54
Oct 18, 2017: New study reveals breast cancer cells recycle their own ammonia waste as fuel 55
Oct 09, 2017: New Congenital Heart Disease Genes Uncovered 57
Sep 15, 2017: New Study on the Placebo Effect and Antidepressants in Children and Adolescents 58
Sep 11, 2017: Scientists Construct First Predictive Model of Inflammatory Bowel Disease 59
Aug 31, 2017: Role of gut bacteria in averting Type 1 diabetes 60
Aug 21, 2017: Massachusetts Eye and Ear: Researchers identify key compounds to resolve abnormal vascular growth in age-related macular degeneration 62
Aug 14, 2017: Breakthrough Study By Pancreatic Cancer Action Network Grantee Evaluates Tumor Growth In Obese Vs. Lean Mice 64
Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 65
Jun 27, 2017: Individualizing deep brain stimulation in patients with Parkinson's disease 68
Apr 11, 2017: Researchers identify new target for abnormal blood vessel growth in the eyes 69
Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 70
Product News 72
Jul 02, 2018: New Cancer Immunotherapy Shows Promise in Early Tests 72
Apr 24, 2018: Natural barcodes enable better cell tracking 73
Apr 17, 2017: New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs 75
Other Significant Developments 76
Aug 13, 2018: Predicting risk for common deadly diseases from millions of genetic variants 76
Aug 10, 2018: Study suggests glaucoma may be an autoimmune disease 78
Jul 24, 2018: Alzheimer's-related study: brain training upregulates acetylcholine 80
Jul 05, 2018: Amyloid beta protein protects brain from herpes infection by binding to, entrapping viral particles 81
Jul 04, 2018: Expanding primary care buprenorphine treatment could curb opioid overdose crisis 83
Jun 27, 2018: Patients believed to be allergic to penicillin have significantly increased risks of MRSA and C. difficile 85
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87
List of Figure
List of Figures
Harvard Medical School, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Harvard Medical School, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Harvard Medical School, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Harvard Medical School, Pharmaceuticals & Healthcare, Key Facts 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Harvard Medical School, Deals By Therapy Area, 2012 to YTD 2018 9
Harvard Medical School, Medical Devices Deals, 2012 to YTD 2018 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kiromic Enters into Agreement with Harvard Medical School 13
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 14
Imcare Biotech Enters into Partnership with Harvard Medical School 15
Astellas Pharma Enters into Research Agreement with Harvard Medical School 16
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 17
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Mesoblast Enters into Licensing Agreement with Harvard Medical School 21
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 22
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 23
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School, Key Competitors 27
Harvard Medical School, Key Employees 28
Harvard Medical School, Subsidiaries 29
Harvard Medical School, Joint Venture 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.